UY35165A - Método profiláctico o terapéutico para el síndrome de sjogren - Google Patents

Método profiláctico o terapéutico para el síndrome de sjogren

Info

Publication number
UY35165A
UY35165A UY0001035165A UY35165A UY35165A UY 35165 A UY35165 A UY 35165A UY 0001035165 A UY0001035165 A UY 0001035165A UY 35165 A UY35165 A UY 35165A UY 35165 A UY35165 A UY 35165A
Authority
UY
Uruguay
Prior art keywords
profilactic
therapeutic method
sjogren syndrome
prophylactic
sjogren
Prior art date
Application number
UY0001035165A
Other languages
English (en)
Inventor
Suzuki Nobutaka
Miyazaki Takahiro
Ochi Takashi
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of UY35165A publication Critical patent/UY35165A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención proporciona un agente profiláctico o terapéutico y un método profiláctico o terapéutico superior en la profilaxis o el tratamiento del síndrome de Sjogren. Se proporcionan un agente profiláctico o terapéutico para el síndrome de Sjogren, que contiene un compuesto representado por medio de la fórmula (I): en donde cada símbolo está de acuerdo con lo definido en la Memoria descriptiva.
UY0001035165A 2012-12-04 2013-12-03 Método profiláctico o terapéutico para el síndrome de sjogren UY35165A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261733176P 2012-12-04 2012-12-04
US201361894641P 2013-10-23 2013-10-23

Publications (1)

Publication Number Publication Date
UY35165A true UY35165A (es) 2014-06-30

Family

ID=49885350

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035165A UY35165A (es) 2012-12-04 2013-12-03 Método profiláctico o terapéutico para el síndrome de sjogren

Country Status (5)

Country Link
US (1) US8815887B2 (es)
AR (1) AR093703A1 (es)
TW (1) TW201438717A (es)
UY (1) UY35165A (es)
WO (1) WO2014088113A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210154292A1 (en) * 2019-11-21 2021-05-27 Chemocentryx, Inc. Compositions and Methods for Treating CCR9-Mediated Diseases using CCR9 Inhibitor and Anti-TNF-Alpha Blocking Antibodies
CN113892460A (zh) * 2021-09-29 2022-01-07 滨州医学院 Nod-b6重组近交系小鼠模型的构建方法及应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ536504A (en) 2002-05-24 2008-04-30 Millennium Pharm Inc CCR9 inhibitors and methods of use thereof
PT1562940E (pt) 2002-11-18 2007-07-23 Chemocentryx Inc Sulfonamidas de arilo.
GB0526257D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
GB0526255D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
GB0526252D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
GB0526445D0 (en) 2005-12-23 2006-02-08 Novartis Ag Organic compounds
MX2009008425A (es) 2007-02-06 2009-08-17 Novartis Ag Derivados de 1-bencensulfonil-1h-indol como inhibidores de la actividad de ccr9.
RU2503672C2 (ru) 2008-01-18 2014-01-10 Оксаген Лимитед Соединения, обладающие активностью антагонистов crth2
EP2265581A1 (en) 2008-01-22 2010-12-29 Oxagen Limited Compounds having crth2 antagonist activity
WO2009093029A1 (en) 2008-01-22 2009-07-30 Oxagen Limited Compounds having crth2 antagonist activity
CN107266425B (zh) 2012-02-29 2020-03-03 坎莫森特里克斯公司 作为ccr9拮抗剂的吡唑-1-基苯磺酰胺

Also Published As

Publication number Publication date
AR093703A1 (es) 2015-06-17
US20140155437A1 (en) 2014-06-05
TW201438717A (zh) 2014-10-16
WO2014088113A1 (en) 2014-06-12
US8815887B2 (en) 2014-08-26

Similar Documents

Publication Publication Date Title
PH12017500393A1 (en) Pyrrolopyrimidines for use in influenza virus infection
ECSP12012160A (es) Compuesto heterociclico
PH12017500207A1 (en) Indoles for use in influenza virus infection
IN2015DN01156A (es)
PH12016500486A1 (en) Aza-pyridone compounds and uses thereof
MX2016013689A (es) Compuestos 4-amino-imidazoquinolina.
BR112014021104A2 (pt) métodos e composições para o tratamento da doença de huntington
CO7170160A2 (es) Nuevas 6-aminoacido-heteroarildihidropirimidinas para el tratamiento y profilaxis de la infección del virus de la hepatitis b
MX2016002544A (es) Compuestos utiles como inmunomoduladores.
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
ECSP13012719A (es) Compuesto bicíclico
EA201400178A1 (ru) Лечение рака молочной железы
CR20150211A (es) Compuestos diméricos
CL2016001349A1 (es) Uso de derivados de bencimidazol-prolina
BR112017008481A2 (pt) composto antimicótico
PH12017501071A1 (en) Dihydropyrimidin-2-one compounds and medical use thereof
MX2016001855A (es) Nuevos aza-oxo-indoles para el tratamiento y profilaxis de la infeccion por virus sincitial respiratorio.
CR20150417A (es) Compuestos de azetidiniloxifenilpirrolidina
BR112017013286A2 (pt) composto de isoxazolina, e, uso de um composto de isoxazolina.
EA201491581A1 (ru) Везикулярные композиции
BR112014026813A2 (pt) espaçadores de implante mamário para o tratamento de infecções de implante mamário periprostético
EA201790973A1 (ru) A-антагонист в низкой дозировке для лечения adhd и болезни паркинсона
UY35165A (es) Método profiláctico o terapéutico para el síndrome de sjogren
PH12015502703A1 (en) Pharmaceutical compositions
AR098670A1 (es) Inhibidor de sglt1